Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 16, 2020 - Issue
Submit an article Journal homepage
91
Views
2
CrossRef citations to date
0
Altmetric
Case report

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma

Shinkichi Takamori1 Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka811-1395, Japan
,
Takashi Seto1 Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka811-1395, JapanCorrespondence[email protected]
,
Mikako Jinnouchi2 Department of Radiology, National Hospital Organization Kyushu Cancer Center, Fukuoka811-1395, JapanORCID Iconhttps://orcid.org/0000-0003-3249-6453
ORCID Icon,
Taro Oba1 Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka811-1395, Japan
,
Masafumi Yamaguchi1 Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka811-1395, Japan
&
Mitsuhiro Takenoyama1 Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka811-1395, Japan
Pages 17-20 | Published online: 17 Jan 2020

References

  • Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–1203. doi:10.1016/j.cell.2007.11.025
  • Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863–870. doi:10.1200/JCO.2011.35.6345
  • Yasuda H, de Figueiredo-pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012;7:1086–1090. doi:10.1097/JTO.0b013e3182570919
  • Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–1971. doi:10.1056/NEJMoa1406766
  • Wu YL, Yang JC, Kim DW, et al. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:1405–1411. doi:10.1200/JCO.2017.75.5587
  • Postel M, Kerboull M. Total prosthetic replacement in rapidly destructive arthrosis of the hip joint. Clinical Orthopaedics and Related Research. 1970;72:138–144.
  • Yoshino K, Momohara S, Ikari K, et al. Acute destruction of the hip joints and rapid resorption of femoral head in patients with rheumatoid arthritis. Mod Rheumatol. 2006;16:395–400. doi:10.3109/s10165-006-0516-0
  • Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a Phase 1 study. Lancet Oncol. 2012;13:1011–1019. doi:10.1016/S1470-2045(12)70344-3
  • Guevremont M, Martel-Pelletier J, Massicotte F, et al. Human adult chondrocytes express hepatocyte growth factor (HGF) isoforms but not HgF: potential implication of osteoblasts on the presence of HGF in cartilage. J Bone Miner Res. 2003;18:1073–1081. doi:10.1359/jbmr.2003.18.6.1073
  • Yamakawa T, Sudo A, Tanaka M, Uchida A. Microvascular density of rapidly destructive arthropathy of the hip joint. J Orthop Surg (Hong Kong). 2005;13:40–45. doi:10.1177/230949900501300107

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.